Kindlymd(tm) submits comment to the department of justice regarding cannabis rescheduling

Salt lake city, ut / accesswire / july 25, 2024 / kindlymd, inc. ("kindlymd" or the "company") (nasdaq:kdly), a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, announced today that it has submitted a comment to the u.s. department of justice, following its recent proposed rule to reclassify cannabis from schedule i to schedule iii of the controlled substances act ("csa"), consistent with the view of the department of health and human services ("hhs") that cannabis has a currently accepted medical use as well as hhs's views concerning cannabis abuse potential and the level of physical or psychological dependence. for the past 54 years, cannabis has been categorized as a schedule i controlled substance under the controlled substances act.
KDLY Ratings Summary
KDLY Quant Ranking